We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $2.54, demonstrating a +1.2% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 1.19%.
The maker of genetic analysis technology's shares have seen an increase of 93.08% over the last month, surpassing the Medical sector's loss of 3.74% and the S&P 500's gain of 0.55%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. The company's upcoming EPS is projected at -$0.13, signifying a 8.33% drop compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $37.86 million, indicating a 1.51% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and revenue of $156.1 million, which would represent changes of +18.87% and -2.44%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Pacific Biosciences of California possesses a Zacks Rank of #4 (Sell).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $2.54, demonstrating a +1.2% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 1.19%.
The maker of genetic analysis technology's shares have seen an increase of 93.08% over the last month, surpassing the Medical sector's loss of 3.74% and the S&P 500's gain of 0.55%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. The company's upcoming EPS is projected at -$0.13, signifying a 8.33% drop compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $37.86 million, indicating a 1.51% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and revenue of $156.1 million, which would represent changes of +18.87% and -2.44%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Pacific Biosciences of California possesses a Zacks Rank of #4 (Sell).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.